Cumberland Pharmaceuticals Inc. (CPIX) Financial Statements (2024 and earlier)

Company Profile

Business Address 2525 WEST END AVENUE
NASHVILLE,, TN 37203
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18,24916,38619,75819,54218,21717,267
Cash and cash equivalents18,24916,38619,75819,54218,21717,267
Receivables12,21914,52913,16415,23313,27614,635
Inventory, net of allowances, customer advances and progress billings10,92810,1809,86410,6489,4209,879
Inventory10,92810,1809,86410,6489,4209,879
Other current assets2,2782,715 3,7392,8353,561
Other undisclosed current assets   3,085   
Total current assets:43,67443,81145,87049,16143,74845,342
Noncurrent Assets
Inventory, Noncurrent6,6947,5347,5277,49710,37410,594
Operating lease, right-of-use asset6,8324,9195,218220493761
Property, plant and equipment384355284491457409
Intangible assets, net (including goodwill)29,18430,30431,50530,98134,90836,412
Goodwill9149149141,9331,9331,933
Intangible assets, net (excluding goodwill)28,27029,39030,59129,04832,97534,479
Other noncurrent assets2,6072,5452,5212,4272,5373,179
Total noncurrent assets:45,70145,65847,05541,61648,76951,355
TOTAL ASSETS:89,37589,46992,92590,77792,51896,697
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,91211,22228,40711,51110,59211,448
Accounts payable10,91211,22210,81911,51110,59211,448
Accrued liabilities   17,588   
Other liabilities15,72614,327 13,56613,14812,343
Other undisclosed current liabilities321158173230512766
Total current liabilities:26,95925,70728,58025,30624,25224,557
Noncurrent Liabilities
Long-term debt and lease obligation13,14816,07216,20017,70019,00020,023
Long-term debt, excluding current maturities13,14816,07216,20017,70019,00020,000
Liabilities, other than long-term debt12,43111,64012,171   
Other liabilities6,9547,0917,585   
Operating lease, liability5,4774,5494,586  23
Other undisclosed noncurrent liabilities    9,27910,06111,301
Total noncurrent liabilities:25,57927,71328,37126,97929,06131,346
Total liabilities:52,53853,42056,95152,28553,31355,904
Equity
Equity, attributable to parent, including:37,15936,36136,26638,76439,46341,023
Common stock47,30347,377 47,53247,82248,047
Accumulated deficit(10,144)(11,017)(11,209)(8,768)(8,359)(7,024)
Other undisclosed equity, attributable to parent   47,475   
Equity, attributable to noncontrolling interest(322)(312)(292)(273)(259)(230)
Total equity:36,83736,04835,97438,49139,20440,793
TOTAL LIABILITIES AND EQUITY:89,37589,46992,92590,77792,51896,697

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues10,8899,2259,12411,41310,29911,175
Other income 9821,847    
Cost of revenue
(Cost of Goods and Services Sold)
(1,521)(1,250)(2,650)(2,224)(2,032)(2,212)
Gross profit:9,3687,9746,4739,1898,2678,963
Operating expenses(9,345)(9,506)(8,751)(9,477)(10,114)(10,255)
Operating income (loss):23(1,532)(2,278)(289)(1,847)(1,292)
Nonoperating income
(Investment Income, Nonoperating)
5750657221516
Interest and debt expense(193)(186)(179)(149)(138)(120)
Loss from continuing operations before equity method investments, income taxes:(113)(1,668)(1,800)(416)(1,969)(1,396)
Other undisclosed income (loss) from continuing operations before income taxes9821,847(611) 611 
Income (loss) from continuing operations before income taxes:869179(2,412)(416)(1,358)(1,396)
Income tax expense(7)(7)(48)(7)(7)(7)
Income (loss) from continuing operations:862172(2,460)(423)(1,365)(1,402)
Loss before gain (loss) on sale of properties:(423)(1,365)(1,402)
Net income (loss):862172(2,460)(423)(1,365)(1,402)
Net income attributable to noncontrolling interest102019152917
Net income (loss) available to common stockholders, diluted:872192(2,441)(409)(1,336)(1,385)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):862172(2,460)(423)(1,365)(1,402)
Comprehensive income (loss):862172(2,460)(423)(1,365)(1,402)
Comprehensive income, net of tax, attributable to noncontrolling interest102019152917
Comprehensive income (loss), net of tax, attributable to parent:872192(2,441)(409)(1,336)(1,385)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: